This report provides a comprehensive analysis of the global psychiatric long-acting injection market, forecasting significant growth and evolving trends through 2032. It examines key market segments by product type, such as Aripiprazole and Paliperidone, and applications including schizophrenia and bipolar disorder. Covering major regions like the Americas, APAC, and Europe, the study evaluates competitive landscapes, manufacturer strategies, and emerging opportunities. Detailed insights into market drivers and industry dynamics help stakeholders understand the current trajectory and future potential of this specialized pharmaceutical sector.

Executive Overview

Global Market Outlook

The global Psychiatric Long-acting Injection market is projected to experience significant growth from 2025 through 2032, expanding at a steady compound annual growth rate during the forecast period from 2026 to 2032.

Regional Market Projections

• United States: The market for Psychiatric Long-acting Injection in the United States is estimated to increase from 2025 through 2032, growing at a sustained compound annual growth rate.
• China: The market for Psychiatric Long-acting Injection in China is estimated to see upward growth from 2025 to 2032, following a consistent compound annual growth rate.
• Europe: The European market for Psychiatric Long-acting Injection is projected to expand between 2025 and 2032, characterized by a steady compound annual growth rate.

Report Scope and Methodology

Research Overview

LP Information, Inc. (LPI)'s newest research report, the “Psychiatric Long-acting Injection Industry Forecast,” reviews total world Psychiatric Long-acting Injection sales in 2025. The report provides a comprehensive analysis of projected sales for the period of 2026 through 2032, broken down by region, market sector, and sub-sector. All detailed analyses are provided in US$ millions.

Analytical Depth

This Insight Report provides a comprehensive analysis of the global Psychiatric Long-acting Injection landscape, highlighting key trends related to:

• Product segmentation
• Company formation
• Revenue and market share
• Latest developments
• M&A activity

The report also analyzes the strategies of leading global companies, focusing on their Psychiatric Long-acting Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints to better understand their unique positions in an accelerating global market.

Strategic Insights

The report evaluates key market trends, drivers, and affecting factors shaping the global outlook. It breaks down the forecast by Type, Application, geography, and market size to highlight emerging pockets of opportunity. Utilizing a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study offers a highly nuanced view of the current state and future trajectory of the global Psychiatric Long-acting Injection industry.

Market Segmentation

Segmentation by Type

• Aripiprazole Long-acting Injection
• Haloperidol Long-acting Injection
• Paliperidone Long-acting Injection
• Risperidone Long-acting Injection
• Olanzapine Long-acting Injection
• Others

Segmentation by Application

• Schizophrenia
• Bipolar Disorder
• Others

Segmentation by Region

• Americas: United States, Canada, Mexico, Brazil
• APAC: China, Japan, Korea, Southeast Asia, India, Australia
• Europe: Germany, France, UK, Italy, Russia
• Middle East & Africa: Egypt, South Africa, Israel, Turkey, GCC Countries

Competitive Landscape

Market Dynamics

The global key Psychiatric Long-acting Injection players include Oakwood Labs, Teva, MedinCell, Janssen, and Otsuka America Pharmaceutical, Inc. In terms of revenue, the global two largest companies occupied a significant portion of the market share in 2025.

Profiled Companies

The following companies have been selected based on inputs gathered from primary experts and analysis of their coverage, product portfolio, and market penetration:

• Oakwood Labs
• Teva
• MedinCell
• Janssen
• Otsuka America Pharmaceutical, Inc.
• Lundbeck
• Eli Lilly
• Alkermes
• Par Pharmaceutical
• AbbVie
• Luye Pharmaceutical

Key Questions Addressed

• What is the 10-year outlook for the global Psychiatric Long-acting Injection market?
• What factors are driving Psychiatric Long-acting Injection market growth, globally and by region?
• Which technologies are poised for the fastest growth by market and region?
• How do Psychiatric Long-acting Injection market opportunities vary by end market size?
• How does Psychiatric Long-acting Injection break out by Type and by Application?

• 1 Scope of the Report

  • 1.1 Market Introduction

  • 1.2 Years Considered

  • 1.3 Research Objectives

  • 1.4 Market Research Methodology

  • 1.5 Research Process and Data Source

  • 1.6 Economic Indicators

  • 1.7 Currency Considered

  • 1.8 Market Estimation Caveats

• 2 Executive Summary

  • 2.1 World Market Overview

    • 2.1.1 Global Psychiatric Long-acting Injection Annual Sales 2021-2032

    • 2.1.2 World Current & Future Analysis for Psychiatric Long-acting Injection by Geographic Region, 2021, 2025 & 2032

    • 2.1.3 World Current & Future Analysis for Psychiatric Long-acting Injection by Country/Region, 2021, 2025 & 2032

  • 2.2 Psychiatric Long-acting Injection Segment by Type

    • 2.2.1 Aripiprazole Long-acting Injection

    • 2.2.2 Haloperidol Long-acting Injection

    • 2.2.3 Paliperidone Long-acting Injection

    • 2.2.4 Risperidone Long-acting Injection

    • 2.2.5 Olanzapine Long-acting Injection

    • 2.2.6 Others

    • 2.2.7 Psychiatric Long-acting Injection Sales by Type

      • 2.2.7.1 Global Psychiatric Long-acting Injection Sales Market Share by Type (2021-2026)
      • 2.2.7.2 Global Psychiatric Long-acting Injection Revenue and Market Share by Type (2021-2026)
      • 2.2.7.3 Global Psychiatric Long-acting Injection Sale Price by Type (2021-2026)

  • 2.3 Psychiatric Long-acting Injection Segment by Application

    • 2.3.1 Schizophrenia

    • 2.3.2 Bipolar Disorder

    • 2.3.3 Others

    • 2.3.4 Psychiatric Long-acting Injection Sales by Application

      • 2.3.4.1 Global Psychiatric Long-acting Injection Sale Market Share by Application (2021-2026)
      • 2.3.4.2 Global Psychiatric Long-acting Injection Revenue and Market Share by Application (2021-2026)
      • 2.3.4.3 Global Psychiatric Long-acting Injection Sale Price by Application (2021-2026)

• 3 Global by Company

  • 3.1 Global Psychiatric Long-acting Injection Breakdown Data by Company

    • 3.1.1 Global Psychiatric Long-acting Injection Annual Sales by Company (2021-2026)

    • 3.1.2 Global Psychiatric Long-acting Injection Sales Market Share by Company (2021-2026)

  • 3.2 Global Psychiatric Long-acting Injection Annual Revenue by Company (2021-2026)

    • 3.2.1 Global Psychiatric Long-acting Injection Revenue by Company (2021-2026)

    • 3.2.2 Global Psychiatric Long-acting Injection Revenue Market Share by Company (2021-2026)

  • 3.3 Global Psychiatric Long-acting Injection Sale Price by Company

  • 3.4 Key Manufacturers Psychiatric Long-acting Injection Producing Area Distribution, Sales Area, Product Type

    • 3.4.1 Key Manufacturers Psychiatric Long-acting Injection Product Location Distribution

    • 3.4.2 Players Psychiatric Long-acting Injection Products Offered

  • 3.5 Market Concentration Rate Analysis

    • 3.5.1 Competition Landscape Analysis

    • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

  • 3.6 New Products and Potential Entrants

  • 3.7 Market M&A Activity & Strategy

• 4 World Historic Review for Psychiatric Long-acting Injection by Geographic Region

  • 4.1 World Historic Psychiatric Long-acting Injection Market Size by Geographic Region (2021-2026)

    • 4.1.1 Global Psychiatric Long-acting Injection Annual Sales by Geographic Region (2021-2026)

    • 4.1.2 Global Psychiatric Long-acting Injection Annual Revenue by Geographic Region (2021-2026)

  • 4.2 World Historic Psychiatric Long-acting Injection Market Size by Country/Region (2021-2026)

    • 4.2.1 Global Psychiatric Long-acting Injection Annual Sales by Country/Region (2021-2026)

    • 4.2.2 Global Psychiatric Long-acting Injection Annual Revenue by Country/Region (2021-2026)

  • 4.3 Americas Psychiatric Long-acting Injection Sales Growth

  • 4.4 APAC Psychiatric Long-acting Injection Sales Growth

  • 4.5 Europe Psychiatric Long-acting Injection Sales Growth

  • 4.6 Middle East & Africa Psychiatric Long-acting Injection Sales Growth

• 5 Americas

  • 5.1 Americas Psychiatric Long-acting Injection Sales by Country

    • 5.1.1 Americas Psychiatric Long-acting Injection Sales by Country (2021-2026)

    • 5.1.2 Americas Psychiatric Long-acting Injection Revenue by Country (2021-2026)

  • 5.2 Americas Psychiatric Long-acting Injection Sales by Type (2021-2026)

  • 5.3 Americas Psychiatric Long-acting Injection Sales by Application (2021-2026)

  • 5.4 United States

  • 5.5 Canada

  • 5.6 Mexico

  • 5.7 Brazil

• 6 APAC

  • 6.1 APAC Psychiatric Long-acting Injection Sales by Region

    • 6.1.1 APAC Psychiatric Long-acting Injection Sales by Region (2021-2026)

    • 6.1.2 APAC Psychiatric Long-acting Injection Revenue by Region (2021-2026)

  • 6.2 APAC Psychiatric Long-acting Injection Sales by Type (2021-2026)

  • 6.3 APAC Psychiatric Long-acting Injection Sales by Application (2021-2026)

  • 6.4 China

  • 6.5 Japan

  • 6.6 South Korea

  • 6.7 Southeast Asia

  • 6.8 India

  • 6.9 Australia

  • 6.10 China Taiwan

• 7 Europe

  • 7.1 Europe Psychiatric Long-acting Injection by Country

    • 7.1.1 Europe Psychiatric Long-acting Injection Sales by Country (2021-2026)

    • 7.1.2 Europe Psychiatric Long-acting Injection Revenue by Country (2021-2026)

  • 7.2 Europe Psychiatric Long-acting Injection Sales by Type (2021-2026)

  • 7.3 Europe Psychiatric Long-acting Injection Sales by Application (2021-2026)

  • 7.4 Germany

  • 7.5 France

  • 7.6 UK

  • 7.7 Italy

  • 7.8 Russia

• 8 Middle East & Africa

  • 8.1 Middle East & Africa Psychiatric Long-acting Injection by Country

    • 8.1.1 Middle East & Africa Psychiatric Long-acting Injection Sales by Country (2021-2026)

    • 8.1.2 Middle East & Africa Psychiatric Long-acting Injection Revenue by Country (2021-2026)

  • 8.2 Middle East & Africa Psychiatric Long-acting Injection Sales by Type (2021-2026)

  • 8.3 Middle East & Africa Psychiatric Long-acting Injection Sales by Application (2021-2026)

  • 8.4 Egypt

  • 8.5 South Africa

  • 8.6 Israel

  • 8.7 Turkey

  • 8.8 GCC Countries

• 9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers & Growth Opportunities

  • 9.2 Market Challenges & Risks

  • 9.3 Industry Trends

• 10 Manufacturing Cost Structure Analysis

  • 10.1 Raw Material and Suppliers

  • 10.2 Manufacturing Cost Structure Analysis of Psychiatric Long-acting Injection

  • 10.3 Manufacturing Process Analysis of Psychiatric Long-acting Injection

  • 10.4 Industry Chain Structure of Psychiatric Long-acting Injection

• 11 Marketing, Distributors and Customer

  • 11.1 Sales Channel

    • 11.1.1 Direct Channels

    • 11.1.2 Indirect Channels

  • 11.2 Psychiatric Long-acting Injection Distributors

  • 11.3 Psychiatric Long-acting Injection Customer

• 12 World Forecast Review for Psychiatric Long-acting Injection by Geographic Region

  • 12.1 Global Psychiatric Long-acting Injection Market Size Forecast by Region

    • 12.1.1 Global Psychiatric Long-acting Injection Forecast by Region (2027-2032)

    • 12.1.2 Global Psychiatric Long-acting Injection Annual Revenue Forecast by Region (2027-2032)

  • 12.2 Americas Forecast by Country (2027-2032)

  • 12.3 APAC Forecast by Region (2027-2032)

  • 12.4 Europe Forecast by Country (2027-2032)

  • 12.5 Middle East & Africa Forecast by Country (2027-2032)

  • 12.6 Global Psychiatric Long-acting Injection Forecast by Type (2027-2032)

  • 12.7 Global Psychiatric Long-acting Injection Forecast by Application (2027-2032)

• 13 Key Players Analysis

  • 13.1 Oakwood Labs

    • 13.1.1 Oakwood Labs Company Information

    • 13.1.2 Oakwood Labs Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.1.3 Oakwood Labs Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.1.4 Oakwood Labs Main Business Overview

    • 13.1.5 Oakwood Labs Latest Developments

  • 13.2 Teva

    • 13.2.1 Teva Company Information

    • 13.2.2 Teva Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.2.3 Teva Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.2.4 Teva Main Business Overview

    • 13.2.5 Teva Latest Developments

  • 13.3 MedinCell

    • 13.3.1 MedinCell Company Information

    • 13.3.2 MedinCell Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.3.3 MedinCell Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.3.4 MedinCell Main Business Overview

    • 13.3.5 MedinCell Latest Developments

  • 13.4 Janssen

    • 13.4.1 Janssen Company Information

    • 13.4.2 Janssen Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.4.3 Janssen Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.4.4 Janssen Main Business Overview

    • 13.4.5 Janssen Latest Developments

  • 13.5 Otsuka America Pharmaceutical, Inc.

    • 13.5.1 Otsuka America Pharmaceutical, Inc. Company Information

    • 13.5.2 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.5.3 Otsuka America Pharmaceutical, Inc. Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.5.4 Otsuka America Pharmaceutical, Inc. Main Business Overview

    • 13.5.5 Otsuka America Pharmaceutical, Inc. Latest Developments

  • 13.6 Lundbeck

    • 13.6.1 Lundbeck Company Information

    • 13.6.2 Lundbeck Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.6.3 Lundbeck Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.6.4 Lundbeck Main Business Overview

    • 13.6.5 Lundbeck Latest Developments

  • 13.7 Eli Lilly

    • 13.7.1 Eli Lilly Company Information

    • 13.7.2 Eli Lilly Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.7.3 Eli Lilly Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.7.4 Eli Lilly Main Business Overview

    • 13.7.5 Eli Lilly Latest Developments

  • 13.8 Alkermes

    • 13.8.1 Alkermes Company Information

    • 13.8.2 Alkermes Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.8.3 Alkermes Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.8.4 Alkermes Main Business Overview

    • 13.8.5 Alkermes Latest Developments

  • 13.9 Par Pharmaceutical

    • 13.9.1 Par Pharmaceutical Company Information

    • 13.9.2 Par Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.9.3 Par Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.9.4 Par Pharmaceutical Main Business Overview

    • 13.9.5 Par Pharmaceutical Latest Developments

  • 13.10 AbbVie

    • 13.10.1 AbbVie Company Information

    • 13.10.2 AbbVie Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.10.3 AbbVie Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.10.4 AbbVie Main Business Overview

    • 13.10.5 AbbVie Latest Developments

  • 13.11 Luye Pharmaceutical

    • 13.11.1 Luye Pharmaceutical Company Information

    • 13.11.2 Luye Pharmaceutical Psychiatric Long-acting Injection Product Portfolios and Specifications

    • 13.11.3 Luye Pharmaceutical Psychiatric Long-acting Injection Sales, Revenue, Price and Gross Margin (2021-2026)

    • 13.11.4 Luye Pharmaceutical Main Business Overview

    • 13.11.5 Luye Pharmaceutical Latest Developments

• 14 Research Findings and Conclusion